From the initial screen and its subsequent validation/confirmation, neuroendocrine neoplasms were identified as sensitive to the effect of the NAMPT inhibitors (GMX-1178 and STF-118804). The gene discussed is NAMPT; the disease is neuroendocrine neoplasm.